Andreas Michalsen

Bedeutung für die Hirudotherapie

Andreas Michalsen authored the trial that single-handedly moved hirudotherapy from 'plausible alternative therapy' to evidence-based medicine in the eyes of Cochrane, the BMJ, and the German guideline ecosystem. The 2003 Annals of Internal Medicine RCT — 51 patients with symptomatic medial-compartment knee osteoarthritis randomized to either a single application of 4-6 Hirudo verbana leeches over the affected joint or topical diclofenac gel twice daily for 28 days — demonstrated a 64% reduction in WOMAC pain score at 7 days (P < 0.001) and persistent benefit at 90 days. The result was so large and the methodology so rigorous that the editors of Annals of Internal Medicine published an accompanying editorial calling for further trials in other joints. Michalsen's subsequent decade of work systematically extended the indications: lateral epicondylitis (2008, positive), carpometacarpal arthritis (2008, positive in collaboration with Andereya), and carpal tunnel syndrome (2012, positive). Each trial used identical Biopharm-sourced Hirudo verbana, identical application protocols (4-6 leeches per site, single session), and identical CONSORT-compliant outcome reporting. This consistency allowed Lauche's later meta-analyses to pool the data with confidence — yielding effect sizes that survived sensitivity analyses for risk-of-bias, publication-bias correction, and small-study effects. Beyond the trials themselves, Michalsen's institutional role at Charité — Germany's most prestigious academic medical center, dating from 1710 — gave hirudotherapy the academic gravitas it had lacked since Markwardt's death. The Charité integrative medicine department now treats approximately 8,000 leech-therapy patients annually under full statutory health insurance reimbursement (GKV coding GOÄ-Ziffer 753) and trains roughly 60 German physicians per year in evidence-based application protocols. ASH considers Michalsen the single most influential living clinician in hirudotherapy: the man who made the leech respectable in 21st-century academic medicine.